Announcement

Collapse
No announcement yet.

PLoS One . Research to evaluate safety and impact of long COVID intervention with Ensitrelvir for National Cohort (RESILIENCE Study): A protocol for a randomized, double-blind, placebo-controlled trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • PLoS One . Research to evaluate safety and impact of long COVID intervention with Ensitrelvir for National Cohort (RESILIENCE Study): A protocol for a randomized, double-blind, placebo-controlled trial

    PLoS One


    . 2025 Nov 3;20(11):e0335609.
    doi: 10.1371/journal.pone.0335609. eCollection 2025. Research to evaluate safety and impact of long COVID intervention with Ensitrelvir for National Cohort (RESILIENCE Study): A protocol for a randomized, double-blind, placebo-controlled trial

    Keiji Konishi 1 2 3 , Shungo Yamamoto 2 4 5 , Ryuichi Minoda Sada 2 4 5 , Kento Asano 6 , Daisuke Onozuka 1 2 , Shintaro Tanaka 7 , Shogo Miyazawa 8 , Masahiro Kinoshita 9 , Satoshi Kutsuna 1 2 4 5



    AffiliationsAbstract

    This study was registered with the Japan Registry of Clinical Trials on February 16, 2024 (jRCTs051230184, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs051230184).




    Copyright: © 2025 Konishi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    PubMed Disclaimer
    Conflict of interest statement

    Keiji Konishi, Daisuke Onozuka, and Satoshi Kutsuna have received research support from Shionogi & Co., Ltd., Tokyo, Japan. Shungo Yamamoto, Ryuichi Minoda Sada, Kento Asano declare no competing interests. Shintaro Tanaka, Shogo Miyazawa, and Masahiro Kinoshita are full-time employees of Shionogi & Co., Ltd., and may hold stock in the company. This does not alter our adherence to PLOS ONE policies on sharing data and materials.


Working...
X